Spore-based probiotics are safe for most healthy adults. The most well-studied strains have earned “Generally Recognized as Safe” (GRAS) status from the FDA, and clinical trials consistently show only mild, temporary side effects in healthy participants. That said, spore probiotics carry real risks for people with weakened immune systems, and not all Bacillus strains are equal when it comes to safety.
What Makes Spore Probiotics Different
Spore probiotics are supplements containing bacteria from the Bacillus genus, a group of microorganisms that can form protective shells called endospores. These shells make the bacteria exceptionally tough. Unlike traditional probiotic strains (like Lactobacillus or Bifidobacterium), which are fragile and often die in stomach acid before reaching the intestines, spore-forming bacteria survive low pH, high bile salt concentrations, and even high temperatures. That durability is the main selling point: more of the bacteria arrive alive in your gut, where they can germinate and become active.
The most common species in supplements are Bacillus subtilis, Bacillus coagulans, and Bacillus clausii. Each strain within those species can behave differently, so safety evidence is strain-specific rather than universal.
FDA and European Safety Status
One of the strongest indicators of safety for any food ingredient is GRAS status from the FDA. Bacillus coagulans GBI-30, 6086 (often called BC30) has been reviewed multiple times and cleared for use in a remarkably wide range of products, from baked goods and beverages to dairy, cereals, and even infant formula at levels up to 200 million CFU per 100 mL. The FDA noted “no known inherent self-limiting levels of use,” meaning the agency identified no dose ceiling that would trigger toxicity concerns in healthy people.
In Europe, the European Food Safety Authority (EFSA) maintains a Qualified Presumption of Safety (QPS) list. Bacillus species can qualify, but each strain must meet specific conditions: confirmed identity, no genes conferring resistance to clinically important antibiotics, and no toxin-producing potential. That last requirement matters because some Bacillus species, particularly Bacillus cereus, are known food-poisoning organisms. The QPS process is designed to catch exactly that kind of risk before a product reaches consumers.
What Clinical Trials Show
Human trials of spore probiotics have generally found them well tolerated. In a controlled study of Bacillus subtilis DE111, six participants in the probiotic group reported adverse events including constipation, flatulence, fatigue, anxiety, and diarrhea. Of those six reports, two were judged unrelated to the supplement. Blood markers for metabolic health, lipids, and inflammation showed no significant changes compared to placebo, suggesting the strain didn’t disrupt normal body chemistry.
These findings are consistent with what researchers see across probiotic studies more broadly. The most common side effects are gastrointestinal: gas, bloating, abdominal cramping, soft stools, or constipation. For most people, these symptoms disappear within a few weeks as the gut adjusts. If bloating or gas persists beyond that window, reducing the dose or switching strains is a reasonable next step.
Antibiotic Resistance: A Legitimate Concern
One safety issue that doesn’t get enough attention is antibiotic resistance. A study analyzing 21 Bacillus isolates from commercial probiotic products sold in China found that every single one was resistant to at least one antibiotic, and each strain carried more than ten resistance genes. A streptomycin resistance gene was detected in all strains tested. Two strains, one of Bacillus subtilis and one of Bacillus cereus, carried resistance genes on plasmids, which are small pieces of DNA that bacteria can transfer to other microorganisms in the gut.
This doesn’t mean every spore probiotic on the shelf poses this risk. It does mean that quality control and strain selection matter enormously. Products from manufacturers that conduct genomic screening for resistance genes and toxin potential offer a meaningful safety advantage over generic or poorly characterized formulations. The EFSA’s requirement that QPS-listed strains must lack acquired antibiotic resistance genes reflects how seriously regulators take this issue.
Risks for Immunocompromised People
For people with severely weakened immune systems, spore probiotics are not reliably safe. A documented case involved a 73-year-old man with chronic lymphocytic leukemia who had been taking Bacillus subtilis spores for over a month before being hospitalized with a fever of 40°C (104°F), mental confusion, and diarrhea. Blood cultures confirmed Bacillus subtilis in his bloodstream, and the infection recurred two weeks later with a second, distinct strain from the same probiotic product. The bacteria had persisted in his intestinal tract and crossed into his blood, something his compromised immune system couldn’t prevent.
This type of event, called bacteremia or septicemia, is rare in healthy individuals. But it illustrates a core principle: live microorganisms of any kind carry inherent risk when the immune system can’t keep them in check. People undergoing chemotherapy, organ transplant recipients on immunosuppressive drugs, and those with advanced immune disorders should treat all live probiotics, spore-based or otherwise, with caution.
How to Choose a Safer Product
Not all spore probiotic supplements are created equal, and the lack of pre-market FDA approval for dietary supplements means quality varies widely. A few practical guidelines can help you reduce risk.
- Look for named, researched strains. A label that lists the full strain designation (like GBI-30, 6086 or DE111) signals that the manufacturer is using a characterized strain with published safety data, not a generic Bacillus culture.
- Avoid Bacillus cereus. This species is a well-known cause of food poisoning and has been flagged by researchers as particularly risky in probiotic products due to its toxin-producing potential.
- Check for third-party testing. Independent verification that a product contains what the label claims, and nothing else, adds a layer of assurance that genomic screening for resistance genes and contaminants has been done.
- Start with a lower dose. If you’re new to spore probiotics, beginning with half the recommended serving for the first week or two can help you gauge your body’s response before increasing.
Most clinical studies use doses in the range of 1 to 2 billion CFU per day, which is the range you’ll find in most single-strain supplements. Multi-strain products sometimes go higher, but more isn’t necessarily better, and higher doses increase the likelihood of temporary digestive discomfort during the adjustment period.